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Nowadays, cellular bioenergetics has become a central issue of investigation in cancer biology. Recently, the met-
abolic activity of the cancer cell has been shown to correlate with a proteomic index that informs of the relative
mitochondrial activity of the cell. Within this new field of investigation, we report herein the production and char-
acterization of high-affinity monoclonal antibodies against proteins of the “bioenergetic signature” of the cell. The
use of recombinant proteins and antibodies against the mitochondrial β-F1-ATPase and Hsp60 proteins and the
enzymes of the glycolytic pathway glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase M2 in quan-
titative assays provide, for the first time, the actual amount of these proteins in normal and tumor surgical speci-
mens of breast, lung, and esophagus. The application of this methodology affords a straightforward proteomic
signature that quantifies the variable energetic demand of human tissues. Furthermore, the results show an un-
anticipated finding: tumors from different tissues and/or histological types have the same proteomic signature of
energetic metabolism. Therefore, the results indicate that cancer abolishes the tissue-specific differences in the
bioenergetic phenotype of mitochondria. Overall, the results support that energetic metabolism represents an ad-
ditional hallmark of the phenotype of the cancer cell and a promising target for the treatment of diverse neoplasias.
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Cancer is a complex genetic disease orchestrated by the acquisition of
gain-of-function mutations in oncogenes and loss-of-function muta-
tions in tumor suppressor genes. Even so, early in this century, the
phenotype of the cancer cell was summarized in six main traits [1].
Almost at the same time, a rebirth of the interest in the energetic
metabolism of cancer spurred [2–4]. Specifically, mechanisms con-
tributing to the “abnormal” aerobic glycolysis of the cancer cell are
being characterized [2–4]. Within this frame, mitochondria have be-
come central players of these studies [5], and consistently, it has been
reported that the relative cellular expression of the bottleneck β-F1-
ATPase (β-F1) protein of oxidative phosphorylation is significantly
diminished in tumors when compared with its levels in normal tis-
sues [6–9]. In certain types of carcinomas, the down-regulation of β-F1
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of the glycolytic pathway [6,8]. This proteomic feature of cancer,
which is fulfilled by more than 95% of the carcinomas analyzed in
large cohorts of different tumors [7,8], defines a “bioenergetic signa-
ture” of potential clinical value as an indicator of disease progression
in colon [6,9], lung [7,10], and breast [8] cancer patients. Further-
more, the bioenergetic signature also affords a predictive marker of
the cellular response to chemotherapy [9,11]. Indeed, the cell death
response to chemotherapeutic agents highly correlated with both the
activity of oxidative phosphorylation [12,13] and the expression of
β-F1 [9,11,14]. This study represents an effort to favor the transla-
tion of the bioenergetic signature of the cell into the clinical setting
by developing the tools that could quantitatively establish the path-
ological range limits of these markers in human neoplasias. Interest-
ingly, it reveals for the first time and irrespective of the cancer type
being considered that energy metabolism has a common protein sig-
nature that provides a generic marker of the cancer cell that might be
exploited in the combat of the disease.
Materials and Methods
Patient Specimens and Protein Extraction
Frozen tissue sections obtained from surgical specimens of un-
treated cancer patients with primary breast and lung adenocarcino-
mas and squamous esophageal and lung carcinomas were obtained
from the Banco de Tejidos y Tumores, IDIBAPS (Instituto de Inves-
tigaciones Biomédicas Pi y Suñer), Hospital Clinic, Barcelona, Spain.
The tissue sections of the tumor and normal tissue of each pa-
tient were analyzed previously by an expert pathologist and the
protein extracted [8]. All tissue samples were anonymized and re-
ceived in a coded form to protect patient confidentiality. The insti-
tutional review board approved the project. Twenty tissue sections
(15 μm) were extracted in 300 μl of 50 mM Tris-HCl pH 8.0 con-
taining 150 mM NaCl, 0.02% (w/v) sodium azide, 0.1% (w/v) SDS,
1% (v/v) Nonidet P40, 0.5% (w/v) sodium deoxycholate, 1 μg/ml
leupeptin, 1 μg/ml antitripsin, 0.4 mM EDTA, 10 mM NaF, and
0.75 mM PMSF at 4°C for 30 minutes. After protein extraction, the
samples were centrifuged (15,000g) at 4°C for 25 minutes. Protein con-
centration in the supernatants was determined with the Bradford reagent
(Bio-Rad, Hercules, CA) using bovine serum albumin as standard.
Cloning Strategies and Protein Expression and Purification
The cDNAs encoding human β-F1 (NP_001677.2), Hsp60
(NP_002147.2), pyruvate kinase (PK; AAH35198), and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; AAF99678) proteins were am-
plified by polymerase chain reaction using theMGC-5231,MGC-4084,
MGC-15908, and MGC-9949 clones, respectively, derived from a
choriocarcinoma (β-F1), uterine (Hsp60), and lung (PK and GAPDH)
tumor cell lines of the ATCC (Manassas, VA) collection. The sequences
of the forward (F) and reverse (R) primers used were as follows: β-F1 (F:
5′-CGGGAGCTCATGTTGGGGTTTGTG-3′; R: 5′-ATAG-
TTTAGCGGCCGCCGATGAATGCTCTTC-3′); Hsp60 (F:
5′-CGGGAGCTCATGCTTCGGTTACCC-3′; R: 5′-CACCACGT-
GAGAACATGCCACCTCC-3′); PK (F: 5′-CGGGAGCTCATG-
TCGAAGCCCCAT-3′ ; R: 5′-ATAGTTTAGCGGCCGC-
CGGCACAGGAACAAC-3′); and GAPDH (F: 5′-CGCGAGCTCAT-
GAACGAAAACCTGTT-3′; R: 5′-CACCACGTGACTCCTTG-
GAGGCCAT-3′). The Sac I, Not I, and Pml I restriction sites are
shown underlined. Amplicons were first cloned into pGEM-Teasyvector (Promega, Madison, WI) and after into pQE-Trisystem. The
resulting plasmids, pQE-β-F1, pQE-Hsp60, pQE-PK, and pQE-
GAPDH, which encode for the proteins with C-terminal 6xHis and
streptavidin tags, were used to transform Escherichia coli M15/pREP4
cells. After induction of protein expression by adding isopropyl-β-thio
galactopranoside (1 mM), the cells were resuspended in buffer A
(100mMNaH2PO4·H2O, 300mMNaCl, pH8.0 supplemented with
lysozyme 1 mg/ml). The expressed proteins were purified using either
Strep-Tactin or metal ion affinity chromatography Ni-NTA superflow
resins (Qiagen, Hilden, Germany). The purity of the proteins was esti-
mated by fractionation on SDS-PAGE.
Monoclonal Antibody Production and ELISAs
BALB/c mice were immunized by intraperitoneal injection with
various dosages of the purified proteins (20 μg). Hybridomas were
produced by fusing spleen cells with myeloma SP2 or NS-1 cells with
polyethylene glycol in HAT-RPMI 1640 medium according to stan-
dard hybridoma techniques. Supernatants of the hybridomas were
screened by indirect ELISA on polystyrene plates coated with the
recombinant proteins (0-150 ng per well). Bound antibodies were
detected using horseradish peroxidase–labeled goat antimouse anti-
bodies (1:1000; DAKO, Carpinteria, CA). After the final washing,
100 μl of OPD solution (Sigma, St. Louis, MO) was added, and
the color reaction was developed for 15 minutes and stopped by
the addition of 18 M H2SO4. Optical density at 490 nm was deter-
mined in a FluoStar Optima (BMG Labtech, Offenburg, Germany)
apparatus. The positive colonies were cloned by limiting dilution.
Mouse monoclonal antibodies were purified with Montage anti-
body purification kit (Millipore, Billerica, MA) according to the sup-
plier’s instructions.
Western and Slot-Blot Procedures
Protein samples were subjected to SDS-PAGE followed by immu-
noblot analysis. A slot-blot apparatus (Schleicher & Schuell, Keene,
NH) was used to print bands of uniform protein density. Protein
samples of purified recombinant proteins (0-40 ng) or of human tis-
sue extracts (0-25 μg) were applied in a final volume of 100 μl to the
wells (Figure 1, D and E ), and the excess of protein binding sites was
blocked with a solution containing 3% bovine serum albumin in
Tris-buffered saline (50 mM Tris-HCI, pH 7.4, 150 mM NaCl).
The membranes were incubated with 0.4 μg/ml of primary antibody
for 60 minutes. The monoclonal antibodies described in this work are
clone 11/21-7 A8 for anti–β-F1, clone 17/9-15 G1 for anti-Hsp60,
clone 273A-E5 for anti-GAPDH, and clone 14/5-21/24 for anti-PK.
Secondary horseradish peroxidase–conjugated goat antimouse anti-
bodies (1:3000) were used for detection by a chemiluminescence detec-
tion method (ECL; Amersham Bioscience, Buckinghamshire, UK).
Membranes were exposed to x-ray films, and the light signals obtained
in the films were quantified only when falling within the linear response
range of the film as shown in the standard curves of the recombinant
proteins and tissue extracts (Figure 1). Quantification of the immuno-
reactive bands (arbitrary units) was accomplished using a Kodak
DC120 Zoom digital camera and the Kodak 1D Image Analysis Soft-
ware for Windows (Kodak, Rochester, NY).
Immunofluorescence Microscopy
Human liver HepG2 and breast Hs578T cancer cells were fixed in
freshly prepared 4% paraformaldehyde in PBS and permeabilized
with a solution containing 0.1% Triton X-100 in PBS for 10 minutes.
Figure 1. Expression and purification of recombinant proteins and characterization of the monoclonal antibodies produced. (A) The M15
E. coli strain was used for the expression of recombinant proteins. Samples were collected before (−) and after 2 hours of 0.1 mM IPTG
induction (+) and the cellular proteins analyzed by SDS-PAGE. The recombinant proteins were affinity-purified using the streptavidin tag
(Hsp60) or the His tag (β-F1 ATPase, GAPDH, and PK) and the purity of the eluted protein estimated by SDS-PAGE (RP). (B) Western blot
analysis showing the reactivity of the different antibodies produced. The antibodies (0.4 μg/ml) exclusively recognized the recombinant
(RP; 1 ng of protein) as well as the native cellular protein in normal and/or tumor breast (B), esophagus (E), gastric (G), and lung (L)
tissues or cell lines (HepG2; 10-30 μg of protein). (C) Immunofluorescence microscopy using the antibodies produced (0.4 μg/ml) re-
vealed (green) the mitochondrial (β-F1 and Hsp60) or cytoplasmic (GAPDH and PK) localization of the cellular proteins in human liver
(HepG2) and breast (Hs578T) cancer cells. Nuclear DNA (blue) was stained with ToPro3. Original magnification, ×60. (D) Representative
slot-blots with the antibodies produced for the quantification of the amount of the different biomarkers. A linear increase in the signal is
observed as the amount of recombinant protein (RP in ng) or protein from cellular extracts (E in μg) is augmented. (E) Graphs of the
experiments in panel D for both the recombinant protein (○, RP) and the cellular antigen (▪, CA) within the linear range of protein. The
equations and correlation coefficients are as follows: β-F1 ATPase [RP: y= 1.7372x − 0.284/R2 = 0.9823; CA: y= 0.7228x+ 0.0542/R2 =
0.9571], Hsp60 [RP: y= 0.3224x− 0.0161/R2 = 9879; CA: y= 0.4594x+ 0.9/R2 = 0.9632], GAPDH [RP: y= 0.243x− 0.0404/R2 = 0.9804;
CA: y = 0.8742x + 0.1839/R2 = 0.992], and PK [RP: y = 0.6673x + 0.179/R2 = 0.9664; CA: y = 1.3235x + 0.3378/R2 = 0.9803].
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the antibodies produced and, after which, were incubated for 45 minutes
with a 1:1000 dilution of goat antimouse immunoglobulin Gs conju-
gated to Alexa 594. Nuclei were stained with ToPro3 (Molecular Probes,
Eugene, OR). Cellular fluorescence was analyzed by confocal micros-
copy using a Bio-Rad Radiance 2000 Zeiss Axiovert S100TV [15].
Statistical Analysis
Statistical analysis was performed using Student’s t test for paired
samples. One-way analysis of variance (ANOVA) was used to detect
differences in the bioenergetic signature within the normal and tumor
biopsies. Standard F test was used to assess significance. Statistical tests
were two-sided at the 5% level of significance. The grouping of bi-
opsies into different subsets with similar degree of similarity was car-
ried out by unsupervised hierarchical clustering based on protein
contents and derived indices of the metabolic biomarkers [8]. Raw
data were normalized to either the mean value of the normal lungsamples that accompany squamous lung carcinomas or the paired nor-
mal tissue and the log 2 of these values used to build up the data
matrix. We used the Cluster Program from “Expression Profiler Clus-
tering home page” (http://ep.ebi.ac.uk/EP/EPCLUST) using the
Euclidean distances and average distance method. In this agglom-
erative clustering procedure, a series of partitions of the data into
Pn, Pn − 1, ..., P1 clusters is achieved. The Pn cluster consists of n
single-biopsy clusters and the last P1 cluster consists of a single group
containing all n biopsies. At a particular stage of the clustering pro-
cedure, the algorithm joins the clusters that are most similar. Simi-
larity in this procedure is defined as the average of distances
between all pairs of objects, where each pair is made up of one biopsy
from each group.
Results
We have recently described [6,8,10] that markers of the bioener-
getic signature of the cell are the catalytic β-F1 of the mitochondrial
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shock protein 60), and the enzymes of the glycolytic pathway
GAPDH and the fetal/tumor M2-PK isoform of PK. To obtain
the recombinant proteins to be used for immunization and as stan-
dards in quantitative assays, we cloned the human cDNA and ex-
pressed the full-length proteins carrying carboxy-terminal 6xHis
and streptavidin tags (Figure 1A). The soluble (Hsp60) and insoluble
(β-F1, GAPDH, and PK) recombinant proteins were purified on
Strep-Tactin and Ni-NTA resins, respectively (Figure 1A), and then
used for mice immunization. Mice were killed for the production of
hybridomas only when a 104 dilution of the serum provided a strong
positive response against the corresponding cellular protein on West-
ern blots (data not shown). Supernatants from the growing hybrido-
mas were screened by indirect ELISA and Western blot analysis.
Only clones producing antibodies of high affinity and specificity in
Western blots (Figure 1B) and in immunocytochemical techniques
(Figure 1C ) were preserved and used for the development of quan-
titative slot-blot assays (Figure 1D). Slot-blots had enough sensitivity
to assess the tissue quantity of these proteins because they have a rel-
atively high cellular representation. Moreover, the signals used for
quantification purposes always fell within the linear response range
of the film for both the recombinant protein assayed and the cellular
antigens (Figure 1E ), validating the assays for quantitative purposes.
The results in Table 1 summarize the content in nanograms per
microgram of cellular protein of β-F1, Hsp60, GAPDH, and PK
in normal and tumor tissues of the lung, esophagus, and breast.
The normalized nondimensional expression values of β-F1 per unit
of structural mitochondrial protein (β-F1/Hsp60 ratio) and per unit
of cellular protein (β-F1/GAPDH ratio) in each tissue are also pre-
sented (Table 1). These two proteomic indexes respectively inform of
the mitochondrial competence and overall cellular activity of mito-
chondria [6,8,10]. The latter ratio, also defined as the bioenergetic
signature of the cell [6], is a proteomic gauge of the activity of aerobic
glycolysis in carcinomas [10]. As shown in Table 1, there is significant
variability in some of these ratios in the normal tissues, especially
in breast, suggesting the existence of heterogeneity in the bioenergetic
phenotype of this tissue as a result of the physiological state of the
patients. The content in normal tissues of the mitochondrial proteins
(β-F1 and Hsp60) is variable (breast > esophagus > lung; Table 1),
most likely reflecting the differential tissue dependence on the bio-
energetic activity of mitochondria for provision of metabolic energy.
Moreover, normal lung biopsies from adenocarcinomas and squa-
mous carcinomas also revealed significant differences in the expres-sion of Hsp60 and in the two ratios derived from β-F1 (Table 1),
further suggesting a heterogeneous distribution/activity of mitochon-
dria within the normal lung. Unsupervised hierarchical clustering of
normal biopsies according to the expression pattern of proteins of the
bioenergetic signature (Table 1) resulted in their distribution into
two main groups (Figure 2A). One of them encompassed breast tis-
sue only and displayed high mitochondrial activity as revealed by the
two ratios used to normalize β-F1 expression (Table 1). The second
group, including the rest of the biopsies (Figure 2A), showed a sig-
nificantly lower content of β-F1 per cell (Table 1), suggesting the
existence of subtle differences in the bioenergetic phenotype of these
tissues. Within this large group, the analysis also illustrates the pref-
erential clustering of esophageal biopsies in a group different from
the normal lung (Figure 2A). Consistent with a heterogeneous activ-
ity of mitochondria within the normal lung, the normal lung tissue
that accompanies adenocarcinomas or squamous carcinomas clus-
tered into two different groups (Figure 2A). The significance of these
differences in the tissue content of all the markers determined and
derived ratios was confirmed by standard F test in one-way ANOVA
model (P < .001).
Consistent with previous qualitative findings on the changes of
these markers in tumors [6–8,10], we observed a significant decrease
in the absolute amount of β-F1 in breast and esophageal carcino-
mas when compared with paired normal tissues (Table 1). In breast
cancer, the sharp reduction in the bioenergetic signature resulted
also from the concurrent and pronounced increase in the content
of Hsp60 and GAPDH in the tumor (Table 1). In esophageal carci-
nomas, only the amount of GAPDH was significantly augmented
(Table 1), contributing also to the reduction of the bioenergetic sig-
nature in this set of carcinomas (Table 1). The changes in the
amount of metabolic markers allowed the correct classification of
normal and tumor breast biopsies by their bioenergetic signature
(Figure 2B). Likewise, the bioenergetic signature also allowed the cor-
rect classification of normal and tumor biopsies of the esophagus
with high specificity (Figure 2C ).
In adenocarcinomas and squamous carcinomas of the lung, we
observed no significant differences in the absolute content of β-F1
when compared with paired normal tissues (Table 1). In squamous
carcinomas of the lung, the absolute tumor content of Hsp60 and
GAPDH were significantly augmented (Table 1), whereas in lung
adenocarcinomas, the two glycolytic markers showed an increase,
although only GAPDH revealed a significant increase when com-
pared with normal lung (Table 1). However, the overall cellularTable 1. Protein Content of Metabolic Biomarkers in Paired Normal and Tumor Samples of the Breast, Esophagus, and Lung.Tissue Biopsy β-F1 Hsp60 GAPDH PK β-F1/Hsp60 β-F1/GAPDHLung Normal (9) 1.37 ± 0.16* 0.19 ± 0.03* 0.30 ± 0.07 0.45 ± 0.07* 7.80 ± 0.84* 5.95 ± 0.91*
Adenocarcinoma (9) 1.43 ± 0.28 0.25 ± 0.05 0.94 ± 0.12† 1.22 ± 0.41 5.63 ± 0.78 2.18 ± 0.86†Lung Normal (9) 0.90 ± 0.17* 0.06 ± 0.02‡ 0.27 ± 0.03 0.52 ± 0.13* 26.20 ± 5.31*,‡ 3.53 ± 0.61*,‡
Squamous (9) 0.77 ± 0.28 0.18 ± 0.04† 0.51 ± 0.02† 0.55 ± 0.19 6.01 ± 1.65† 1.54 ± 0.49†Esophagus Normal (6) 3.36 ± 0.56* 0.36 ± 0.04* 0.54 ± 0.14 1.73 ± 0.39 9.57 ± 1.89 8.48 ± 1.87
Squamous (6) 1.85 ± 0.25† 0.34 ± 0.08 1.09 ± 0.10† 1.44 ± 0.65 6.94 ± 1.26 1.80 ± 0.27†Breast Normal (6) 6.10 ± 0.98 0.03 ± 0.01 0.31 ± 0.11 1.51 ± 0.25 264.33 ± 61.69 39.14 ± 13.95
Adenocarcinoma (6) 2.26 ± 0.45† 0.34 ± 0.13† 2.37 ± 0.39† 0.98 ± 0.29 14.70 ± 4.75† 1.11 ± 0.20†The protein content of β-F1, Hsp60, GAPDH, and PK is expressed in nanograms per microgram of total cellular protein. The ratios derived are dimensionless. The number of biopsies in each group is
shown in parenthesis. The results shown are the mean ± SEM.
*Significance of P ≤ .05 by Student’s t test when compared with normal breast biopsies.
†Significance of P ≤ .05 by Student’s t test when compared with paired normal samples.
‡Significance of P ≤ .05 when comparing the two sets of normal lung biopsies.
Figure 2. Graphical hierarchical clustering analysis of the bioenergetic signature as quantitatively determined by slot-blot procedures.
Rows indicate type of sample; columns, proteins and derived ratios. Protein expression scores are shown normalized to the mean value
of the normal lung samples that accompany squamous lung carcinomas (LSC-N) in panels A, E, and F and to the corresponding normal
tissue in panels B, C and D, according to a color scale (below panel F): red indicates high; black, normal; and green, low. The dendogram
(to the right of the matrix) represents overall similarities in expression profiles. The maximum and minimum values of the markers for
each cluster are shown in brackets. (A) Clustering of normal breast (B-N, light blue), esophageal (ESO-N, orange), and normal lung sam-
ples from adenocarcinomas (LAC-N, yellow) and squamous carcinomas (LSC-N, light green). (B) Clustering of normal (B-N, light blue)
and adenocarcinomas (B-T, black) of the breast. (C) Clustering of normal (ESO-N, orange) and squamous carcinomas (ESO-T, green) of
the esophagus. (D) Clustering of normal (LAC-N, yellow) and adenocarcinomas of the lung (LAC-T, blue). (E) Clustering of normal (LSC-N,
light green) and squamous carcinomas of the lung (LSC-T, red). (F) Clustering of breast, esophageal, and lung tumors.
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squamous carcinomas of the lung showed a significant reduction
when compared with paired normal lung (Table 1), consistent with
previous reports in lung cancer [7,10]. As indicated for the case of
breast and esophageal cancer (Figure 2), the changes in the amount
of metabolic markers allowed the classification of normal and tumor
lung biopsies by their bioenergetic signature (Figure 2, D and E , for
adenocarcinomas and squamous carcinomas, respectively). It seems
that the power of the classification of the biopsies by markers of
energetic metabolism diminishes because the tissue of origin of the
neoplasia is less dependent on the bioenergetic activity of mitochon-
dria (breast > esophagus > lung; Figure 2). It is also possible that the
tumor biopsies misclassified within the normal groups (Figure 2)
could be derived from patients in early stages of their disease, i.e.,
when the bioenergetic phenotype of the cancer cell is still poorly af-
fected [6–8].
Overall, it was remarkable to observe that tumors derived from
different tissues and histological types had the same bioenergetic sig-
nature (β-F1/GAPDH ratio in Table 1; and compare the preferential
red color under β-F1/GAPDH ratio in Figure 2A vs the green color
under β-F1/GAPDH ratio in Figure 2F ), as confirmed by F test in
a one-way ANOVA model. Moreover, unsupervised clustering of
the tumors did not reveal the preferential clustering of the biopsies
within defined subgroups according to the tissue of origin or the his-
tological subtype (Figure 2F ), suggesting the existence of a common
metabolic trait for these types of tumors.Discussion
Previous studies have qualitatively shown that the expression of
proteins of energetic metabolism are useful markers of the metabolic
activity of cancer cells and tumors [10] and in predicting the prog-
nosis of breast [8,16], colon [6,9], and lung [7,10] cancer patients.
Moreover, the tumor expression of β-F1 has been shown to be an
independent marker of survival in breast and lung cancer as assessed
by multivariate Cox regression analysis [8,10]. Recently, these find-
ings have been confirmed in a different large cohort of colon cancer
patients [9]. Thus, the alteration of the bioenergetic signature strongly
supports a relevant role for the mitochondrial impairment of the can-
cer cell in progression of the disease. In addition, these markers also
predict the response to chemotherapy in various cancer cells [11,14]
and in colorectal tumors [9]. Clinical translation of many of the pro-
tein biomarkers of cancer that have been discovered in recent years is
scarce. A reason that limits translation is the lack of quantitative assays
that could minimize the variability in assessing the expression of the
biomarkers between different assays and/or laboratories. Herein, we
describe the production of the recombinant proteins and the mono-
clonal antibodies against the markers of the bioenergetic signature as
well as the implementation of these tools in simple quantitative assays
based on slot-blot procedures to stimulate the translation of the bio-
energetic signature into the clinics. Slot-blot procedures were chosen as
initial methodology to assess the quantity of the biomarkers because
they were easy to implement owing to the relatively high cellular abun-
dance of these proteins and the high affinity and specificity of the
antibodies produced. The availability of the recombinant proteins
and of a set of well-validated monoclonal antibodies against these
markers could now favor its further use in the development of a variety
of other proteomic assays [17,18] to quantify the bioenergetic signa-
ture of human tissues.It is well established that mitochondrial content is very different
depending on the tissue type being considered [19]. This heteroge-
neity in the phenotype of energetic metabolism in normal human
tissues is illustrated by the normalized expression of β-F1 relative
GAPDH (Table 1 and Figure 2A). Moreover, mitochondria itself
are structurally and molecularly different in the various mammalian
cell types, supporting the existence of cell type–specific programs for
controlling the biogenesis and activity of the organelle in each tissue
[20]. In fact, it has been shown that whereas liver carcinogenesis
involves a depletion of the cellular mitochondrial content [6], in
kidney, breast, colon, gastric, esophageal, and lung carcinomas, there
is a selective repression of the expression of β-F1 [6–8,21]. Both
mechanisms limit the mitochondrial activity in the cancer cell, and
consistently, we observe that cancer affects the mitochondrial pheno-
type of the cell in a tissue-specific way (Table 1). Prostate adeno-
carcinomas failed to reveal significant changes in the bioenergetic
signature when compared with paired normal prostate tissue [21],
which might suggest that the regulation of enzymatic activities
by covalent and/or allosteric modification mediates the regulation
of the metabolic flux in carcinogenesis in prostate and, perhaps, in
some other tissues. Because the static protein signature of the β-F1/
GAPDH ratio in the tumors is depicting the dynamic nature of
glucose capture and utilization by aerobic glycolysis [10] and the bio-
energetic signature is applicable in a wide range of neoplasias that
include some of the most prevalent cancers (breast, lung, and colon),
we strongly support its translation to the clinics.
We show that changes in the absolute amount of metabolic bio-
markers provide a clear-cut classification of normal and tumor biop-
sies in a variety of tissues. Consistent with these findings, we have
previously shown by Fischer discriminant analysis in large cohorts
of breast [8] and lung [7] cancer patients that markers of the bio-
energetic signature have classification sensitivity higher than 95%.
More recently, we have shown that the bioenergetic signature (β-F1/
GAPDH ratio) determined in tumors inversely correlates with the
in vivo glucose uptake of lung carcinomas as assessed by positron emis-
sion tomography using 2-deoxy-2-[18F]fluoro-D-glucose as probe [10].
Furthermore, in the same study, we showed that the bioenergetic sig-
nature also correlates inversely with the rates of aerobic glycolysis [10]
and that the β-F1/Hsp60 ratio informs of the rates of oligomycin-
sensitive respiration in colon cancer cells (Sanchez-Aragó and Cuezva,
unpublished observation). Therefore, these results strongly support
that changes in the expression of markers of the bioenergetic signature
are indeed related with functional changes in the metabolic flux of gly-
colysis and of oxidative phosphorylation in cells and tumors. The fre-
quent genetic alterations that occur in tumors and that are known to
affect both mitochondrial and/or glycolytic metabolism are expected to
superimpose to the changes on the expression of the markers of ener-
getic metabolism that are required to sustain cellular proliferation.
Recent findings have established a relevant role for the M2 type of
PK in oncogenesis [22,23] and in the promotion of the metabolic
shift required for tumorigenesis [22]. Interestingly, the data presented
herein with a specific antibody against the M2-PK isoform indicate
that normal breast and esophageal tissues have, when compared
with lung, a higher quantity of this oncofetal protein, providing
the first indication that these human tissues are already outfitted with
the less active isoform of PK [22]. This situation would suggest that
breast, esophageal, and lung tissues are more prone to malignant
transformation. Consistent with this suggestion, carcinogenesis in
these tissues, albeit in lung adenocarcinomas, was not accompanied
144 The Mitochondrial Trait of Cancer Acebo et al. Translational Oncology Vol. 2, No. 3, 2009by changes in the content of the PK-M2, thus indicating that they
are already equipped with enough complement of PK-M2 to sustain
cellular proliferation.
Unexpectedly, we find that tumors from different tissues and/or
histological subtypes have the same cellular content of these markers
and, therefore, the same bioenergetic signature. It seems that cancer
alters the expression of the markers of energetic metabolism of the
cell in a tissue-specific manner (Table 1), consistent with the variable
cellular response that oncogenes [3,24,25] and tumor suppressors
[2,5,26] have on the phenotype of energetic metabolism. However,
it is noteworthy that the bioenergetic signature is basically the same
regardless of the tissue of origin and the histological type of the tu-
mor (see β-F1/GAPDH ratio in Table 1 and Figure 2F ). These find-
ings could support that a common origin for tumors arises from an
undifferentiated progenitor cell and that cancer cells undergo a pro-
cess of dedifferentiation to acquire the traits of embryonic stem cells
[27]. In this regard, we suggest that the bioenergetic signature of the
tumors and, hence, the expression of markers of energetic metab-
olism partially respond to the installment of the reductive meta-
bolic program (mainly glycolytic) that sustains cellular proliferation
[15,28]. Conversely, the suppression of the tissue-specific differences
in the bioenergetic signature of the tumors and its drastic reduction
in certain tissues (Table 1) strongly support that containment of the
mitochondrial bioenergetic activity in the cancer cell is an event re-
quired for tumor progression. Indeed, tumors with a low bioenergetic
signature have a worse prognosis [6–8,10] and the activity of mito-
chondria has been shown to act as a tumor suppressor [12,14,29].
Owing to the convergence of breast, lung, and esophageal tumors
on the same bioenergetic signature, it seems that energetic metabo-
lism affords a common target for cancer therapy. In this regard,
several groups and biotech companies are currently targeting the pro-
teins of energetic metabolism as a promising approach to eradicate
different types of tumors especially in combined therapy [30–33].
Overall, and because the bioenergetic signature provides a predictive
marker of the response of tumors to chemotherapy [9], in agreement
with the role of mitochondrial oxidative phosphorylation in the ex-
ecution of cell death [11,13,14], we suggest that its translation to the
clinics will benefit cancer patients.Acknowledgments
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